Gut Microbiome Profiling in Patients With Chronic Heart Failure
Longitudinal Gut Microbiome and Host Multi-omic Profiling in Patients With Chronic Heart Failure
The goal of this observational study is to learn about the composition and function of the gut microbiome in adults with chronic heart failure with reduced ejection fraction. The main questions the study aims to answer are:
- How does the gut microbiome and its interactions with the host change over time in adults with chronic heart failure?
- How do these changes relate to heart failure disease severity and complications?
Study Overview
Status
Status
Conditions
Conditions
Detailed Description
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Contacts and Locations
Study Locations
-
-
California
-
Stanford, California, United States, 94305-5210
- Stanford University
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Heart failure with reduced ejection fraction (left ventricular ejection fraction less than 50%)
- Non-ischemic cardiomyopathy
- Body mass index (BMI) 18-40 kg/m2
Exclusion Criteria:
- Treated diabetes
- Advanced kidney disease
- Cirrhosis
- Significant gastrointestinal disease including any history of inflammatory bowel disease
- History of extensive bowel resection
- Active malignancy or systemic chemotherapy within the past 12 months
- Active infection
- Current or recent (within 4 weeks) use of systemic antibiotics, commercial probiotics, immunosuppressive or immunomodulatory medications
- Pregnancy/lactation
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
|---|
|
Heart failure
Adults with heart failure with reduced ejection fraction; no intervention
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Advanced heart failure-associated microbiome signatures
Time Frame: 24 months from baseline visit
|
A map of gut microbiome compositional and functional features associated with a composite clinical outcome of advanced heart failure (composite of needing heart transplantation (including active listing), left ventricular assist device implantation, transition to hospice, or death) that occurs within 24 months of baseline visit.
Fecal samples will be collected every 3 months over the first 12 month period.
Microbiota composition will be determined by shotgun metagenomic sequencing, with taxonomic and metabolic pathway signatures generated using bioinformatic pipelines, respectively.
Comprehensive microbiome signatures will encompass alpha and beta diversity, and differential abundance analysis.
|
24 months from baseline visit
|
|
Temporal changes in the gut microbiome community composition in chronic heart failure
Time Frame: 12 months from baseline visit
|
Longitudinal changes in the gut microbiome composition and functionality in chronic heart failure will be determined.
Microbiome signatures will be mapped from fecal samples collected every 3 months over a 12 month period, generated from shotgun metagenomic sequencing data and after processing through bioinformatic pipelines.
|
12 months from baseline visit
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Comprehensive longitudinal metabolome profile in chronic heart failure
Time Frame: 12 months from baseline visit
|
Changes in the host (human) metabolome profile in chronic heart failure with reduced ejection fraction will be determined.
Participants provide fasting blood samples every 3 months for 12 months, from which plasma samples are prepared.
Plasma metabolites are run through liquid chromatography-mass spectrometry (LC-MS) columns.
MetID (Metabolite Identification from a reference database) and our LC-MS data are used to identify hundreds of metabolites with confidence levels 1-2.
Many of the identified metabolites are gut microbiome-derived.
|
12 months from baseline visit
|
|
Comprehensive longitudinal cytokine profile in chronic heart failure
Time Frame: 12 months from baseline visit
|
Changes in the host (human) cytokines in chronic heart failure with reduced ejection fraction will be determined.
Participants provide fasting blood samples every 3 months for 12 months, from which serum samples are prepared.
Cytokines are profiled using a 76-cytokine Luminex profiling system at the Stanford Human Immune Monitoring Center.
This involves attaching antibodies specific to cytokines to beads using a capture molecule.
The fluorescent molecules are attached to the cytokines, and fluorescence is used as the measure of cytokine abundance.
|
12 months from baseline visit
|
|
Longitudinal change in New York Heart Association (NYHA) functional class
Time Frame: 12 months from baseline visit
|
Participants' functional status (as measured by NYHA class, which ranges from 1 to 4, with 1 being no to minimal symptoms with activity, and 4 being symptoms at rest) will be assessed at each study visit for the first 12 months (every 3 months).
|
12 months from baseline visit
|
|
Longitudinal change in the self-reported functional status
Time Frame: 12 months from baseline visit
|
Participant self-reported functional status will be assessed via Kansas City Cardiomyopathy Questionnaire-12, which participant will complete at each study visit (every 3 months for 12 months).
Overall summary and clinical summary scores (each 0-100, with 0 corresponding to severe and 100 corresponding to no functional limitations) will be calculated and compared over visits.
|
12 months from baseline visit
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 44967
- 5F32HL143916 (U.S. NIH Grant/Contract)
- 856341 (Other Grant/Funding Number: American Heart Association)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Time Frame
IPD Sharing Access Criteria
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- ANALYTIC_CODE
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.